This page is intended for health care professionals. For general information about COVID-19 treatment, please visit the COVID-19 Symptoms and Treatment page.
The Food and Drug Administration (FDA) no longer authorizes bebtelovimab or Evusheld for emergency use because they are no longer effective against the most widely circulating variants.
Several treatments have been authorized by the FDA for the outpatient treatment and prevention of COVID-19. Vermont follows the CDC’s guidance for COVID-19 treatment. For hospitalized patients, consult NIH’s Therapeutic Management of Hospitalized Adults With COVID-19.
Clinicians should consider COVID-19 treatment in patients who:
- Test positive for SARS-Cov-2 (with PCR or antigen tests, including at-home tests). (Required for Veklury)
- Have a current diagnosis of SARS-CoV-2 based on exposure and symptoms (allowed for Paxlovid and Lagevrio)
- Have symptoms consistent with mild-to-moderate COVID-19. People with mild COVID-19 experience symptoms, such as fever, sore throat, cough or headache, that do not affect the lungs and breathing. People with moderate illness have symptoms that affect the lungs like shortness of breath or difficulty breathing.
- Are within 5 days of symptom onset for Paxlovid or 7 days of symptom onset for Veklury.
- Have one or more risk factors for severe COVID-19.
- Are not hospitalized (except if considering Veklury).
Age remains the strongest risk factor for severe COVID-19. Therefore, we recommend considering treatment for all patients age 50 and older.
How to select the right COVID-19 therapeutics
The antiviral drugs Paxlovid (ritonavir-boosted nirmatrelvir) and Veklury (remdesivir) are the preferred treatments for eligible adult and pediatric patients with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19. Paxlovid is an oral antiviral taken for 5 consecutive days, while Veklury (remdesivir) is administered via an IV infusion over 3 days. Lagevrio (molnupiravir) may also be considered if no other therapeutic options are available.
Paxlovid Eligibility and Effectiveness Information Sheet
Paxlovid Patient Eligibility Screening Checklist Tool for Prescriber
Use the Liverpool Drug Interaction Checker when considering PaxlovidFind the best treatment with the COVID-19 Therapeutics Decision Aid (ASPR)See chart of available therapeutics with links to product fact sheets (ASPR)
How to order COVID-19 therapeutics
- Use the Therapeutics Locator Tool to find Paxlovid and Lagevrio.* Most pharmacies in Vermont carry Paxlovid.
- Remdesivir is administered via an IV infusion over 3 days at select hospitals in Vermont.
*As of November 30, the Food and Drug Administration (FDA) no longer authorizes bebtelovimab for emergency use because it is not effective against the most widely circulating variants.
Allocation and Distribution of COVID-19 Therapeutics
The federal government continues to supply states and jurisdictions with Paxlovid and Lagevrio. Each jurisdiction sets a threshold for Paxlovid and Lagevrio and each Monday, the federal government replenishes products equal to the amount ordered the previous week.
Remdesivir can be purchased on the commercial marketplace. The Food and Drug Administration (FDA) no longer authorizes bebtelovimab or Evusheld for emergency use because they are no longer effective against the most widely circulating variants.
Vermont hospitals and pharmacies interested in carrying or redistributing COVID-19 therapeutics should email [email protected].
COVID-19 Therapeutics Thresholds, Orders, and Replenishment by Jurisdiction (ASPR)
COVID-19 Shelf-Life Extensions (FDA)
- Interim Clinical Considerations for COVID-19 Treatment in Outpatients (CDC)
- COVID-19 Treatment Guidelines (NIH)
- COVID-19 Therapeutic Product Resources (ASPR)
Videos & Webinars
- COVID‑19 Therapeutic Options Videos (ASPR)
- Updates to Vermont’s COVID-19 Therapeutics Program (VDH)
- Video translations on COVID-19 treatments for patients (VDH)
Health Alert Network (HAN)
For questions about COVID-19 therapeutics in Vermont, email [email protected].